CorMedix (CRMD) 10-Q2019 Q1 Quarterly report

Filed: 13 May 19, 4:46pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: alternative, Antibacterial, Antifungal, authoritative, begun, Black, borrowing, calendar, Century, cited, comparison, consecutive, consent, consented, consummation, context, Counsel, counter, discount, dismissing, distributor, Economic, entirety, entry, equipment, expedite, factor, feature, firmly, fractional, harm, hybrid, implicit, implicitly, incidence, incremental, lieu, LPAD, Manchester, necessity, NJEDA, NOL, noncash, noteholder, ordinary, passed, Phoebe, placement, plasminogen, point, population, portion, prepay, prepayment, prevalence, profile, proportional, publicly, put, rarity, reclassification, rental, resale, restated, ROU, satisfied, senior, simultaneously, space, superior, tissue, topline, tPA, unblinded, unblinding, underwriter, unrelated, unused, waive, warrant

Removed: accept, actively, anniversary, approach, assumed, binding, budget, collection, Connect, consulting, cooperatively, cumulative, custom, deliver, dependent, depict, discrete, documentary, doubt, efficient, enrolled, extension, guarantee, implementation, increasing, informed, largely, length, LLC, lookback, modified, opening, Pharma, prioritize, promised, protocol, purpose, reconciliation, remeasured, reserve, responsibility, retained, retrospective, returned, SAE, shipped, stability, supplemental, supporting, timeline, unchanged, upfront, warranty, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CRMD transcripts

CRMD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CorMedix Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Khoso Baluch, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	CORMEDIX INC.

May 13, 2019	By:	/s/ Khoso Baluch
		Khoso Baluch
		Chief Executive Officer (Principal Executive Officer)